Orexigen

Contrave and cardiology--could this newer weight loss drug help your heart too?

food

Members Only: 

food Contrave (bupropion and naltrexone) is apparently unique. The SEC disclosed that the US patent office gave the 371 patent to Orexigen Therapeutics based on an interim look at the LIGHT study. What this means is that Contrave has a claim for having a POSITIVE IMPACT on cardiovascular results (outcomes) beyond (unrelated to) weight loss.

More to come and most probably from the American College of Cardiology meeting in San Diego this month. Regardless, having strength in weight loss AND HEART disease is a true breakthrough in medicines.

Waiting for weight loss and Contrave

woman with blue face Are you getting blue in the face waiting for a new prescription weight loss drug? Today may be your day. The expert advisory committee of the FDA (Endocrine and Metabolic) recommended that the FDA approve Contrave.

Approval Date: 
Mon, 01/31/2011
Company: 
Orexigen

Contrave and long wait for a new weight loss drug is probably over

food on plate The Endocrine and metabolic committee of the FDA recommended 13-7 to approve the first weight loss drug since 1999. Contrave (a combination of bupropion and naltrexone) was recommended for approval and while the FDA usually follows the vote of its expert committees, it is not bound to do so.

Long wait for weight loss at the FDA

flowers by vase  Once again, a pharmaceutical company has submitted a weight loss product to the FDA. This one is different though, Contrave is a combination of TWO FDA APPROVED PRODUCTS (bupropion and naltrexone). You may remember two previous products which were rejected partially on safety concerns by the FDA.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.